$IPSC

Century Therapeutics (IPSC) presented preclinical data for CNTY-813, a type 1 diabetes therapy, at a diabetes conference. The data showed glycemic control in mice for over 11 months. The company plans to submit an IND application in Q4 2026 and expects initial clinical data in 2H 2027, pending FDA alignment and study completion.

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

Century Therapeutics officer Gregory Russotti plans to sell 2,587 shares, valued at $4,994, under Rule 144. The shares are from vested restricted stock and the sale includes funds to cover tax obligations. Previously, he sold 534 shares for $1,094.

Century Therapeutics officer Douglas Carr filed a Rule 144 notice to sell 1,658 shares, valued at $3,200.77, including shares to cover tax obligations. The shares vest on September 11, 2026, as part of his compensation. Carr previously sold 275 and 254 shares in August and September 2026, respectively.

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Century Therapeutics Appoints Joseph Truitt to Board of Directors PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune dis

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

Century Therapeutics (NASDAQ:IPSC) said abstracts for CNTY-813 were accepted for oral presentations at the 62nd EASD meeting (Sep 28-Oct 2, 2026, Milan) and the Breakthrough T1D Congress (Oct 9-11, 2026, Philadelphia). The iPSC-derived islet therapy uses Allo-Evasion 5.0. Company targets an IND submission in Q4 2026 and expects initial clinical data in H2 2027, citing June preclinical results.

Century Therapeutics (NASDAQ: IPSC) said its abstracts were accepted for oral presentations at EASD 2026 (Sept 28-Oct 2, Milan) and Breakthrough T1D CRC 2026 (Oct 9-11, Philadelphia). Both will feature preclinical data on CNTY-813, an Allo-Evasion 5.0 engineered iPSC-derived islet therapy for type 1 diabetes, with an IND targeted for Q4 2026.

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001850119 0001850119 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report